Logo image of TCBP

TC BIOPHARM HOLDINGS PLC-ADR (TCBP) Stock Price, Quote, News and Overview

NASDAQ:TCBP - Nasdaq - US87807D6085 - ADR - Currency: USD

0.5  -1.04 (-67.53%)

After market: 0.6701 +0.17 (+34.02%)

TCBP Quote, Performance and Key Statistics

TC BIOPHARM HOLDINGS PLC-ADR

NASDAQ:TCBP (3/21/2025, 8:00:01 PM)

After market: 0.6701 +0.17 (+34.02%)

0.5

-1.04 (-67.53%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High523.2
52 Week Low0.5
Market Cap5.13M
Shares10.26M
Float10.26M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)12-13 2022-12-13/bmo
IPO02-23 2022-02-23


TCBP short term performance overview.The bars show the price performance of TCBP in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60 -80

TCBP long term performance overview.The bars show the price performance of TCBP in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of TCBP is 0.5 USD. In the past month the price decreased by -80%. In the past year, price decreased by -99.79%.

TC BIOPHARM HOLDINGS PLC-ADR / TCBP Daily stock chart

TCBP Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.39 329.14B
AMGN AMGEN INC 14.17 150.99B
GILD GILEAD SCIENCES INC 13.33 128.61B
VRTX VERTEX PHARMACEUTICALS INC 1702.9 126.96B
REGN REGENERON PHARMACEUTICALS 13.2 65.88B
ARGX ARGENX SE - ADR 330.52 37.54B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.72B
ONC BEIGENE LTD-ADR N/A 26.39B
BNTX BIONTECH SE-ADR N/A 24.52B
NTRA NATERA INC N/A 20.79B
BIIB BIOGEN INC 7.22 17.39B
SMMT SUMMIT THERAPEUTICS INC N/A 17.30B

About TCBP

Company Profile

TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The company employs 41 full-time employees The company went IPO on 2022-02-23. The firm is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - phase IIb/III pivotal trial in treatment of acute myeloid leukemia using its proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide. Its lead product is TCB-008. In addition to unmodified allogenic GD-Ts for treatment of blood cancers, the Company is also developing an expanded platform for TCB-008 use case in anti-fungal, anti-viral and anti-microbial diseases. Its unmodified cell therapy, used in the treatment of acute myeloid leukemia, is supplied under the name OmnImmune. The company is also developing a range of genetically modified CAR-T products for the treatment of solid cancers.

Company Info

TC BIOPHARM HOLDINGS PLC-ADR

Maxim 1, 2 Parklands Way, Holytown

Motherwell GB

Employees: 41

Company Website: https://www.tcbiopharm.com

Investor Relations: https://www.tcbiopharm.com/news/press-releases

Phone: 441414337557

TC BIOPHARM HOLDINGS PLC-ADR / TCBP FAQ

What is the stock price of TC BIOPHARM HOLDINGS PLC-ADR today?

The current stock price of TCBP is 0.5 USD. The price decreased by -67.53% in the last trading session.


What is the ticker symbol for TC BIOPHARM HOLDINGS PLC-ADR stock?

The exchange symbol of TC BIOPHARM HOLDINGS PLC-ADR is TCBP and it is listed on the Nasdaq exchange.


On which exchange is TCBP stock listed?

TCBP stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for TC BIOPHARM HOLDINGS PLC-ADR stock?

7 analysts have analysed TCBP and the average price target is 48.96 USD. This implies a price increase of 9692% is expected in the next year compared to the current price of 0.5. Check the TC BIOPHARM HOLDINGS PLC-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is TC BIOPHARM HOLDINGS PLC-ADR worth?

TC BIOPHARM HOLDINGS PLC-ADR (TCBP) has a market capitalization of 5.13M USD. This makes TCBP a Nano Cap stock.


How many employees does TC BIOPHARM HOLDINGS PLC-ADR have?

TC BIOPHARM HOLDINGS PLC-ADR (TCBP) currently has 41 employees.


Is TC BIOPHARM HOLDINGS PLC-ADR (TCBP) expected to grow?

The Revenue of TC BIOPHARM HOLDINGS PLC-ADR (TCBP) is expected to decline by -100% in the next year. Check the estimates tab for more information on the TCBP EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy TC BIOPHARM HOLDINGS PLC-ADR (TCBP) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does TC BIOPHARM HOLDINGS PLC-ADR (TCBP) stock pay dividends?

TCBP does not pay a dividend.


When does TC BIOPHARM HOLDINGS PLC-ADR (TCBP) report earnings?

TC BIOPHARM HOLDINGS PLC-ADR (TCBP) will report earnings on 2022-12-13, before the market open.


What is the Price/Earnings (PE) ratio of TC BIOPHARM HOLDINGS PLC-ADR (TCBP)?

TC BIOPHARM HOLDINGS PLC-ADR (TCBP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.21).


What is the Short Interest ratio of TC BIOPHARM HOLDINGS PLC-ADR (TCBP) stock?

The outstanding short interest for TC BIOPHARM HOLDINGS PLC-ADR (TCBP) is 0.41% of its float. Check the ownership tab for more information on the TCBP short interest.


TCBP Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

TCBP Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to TCBP. Both the profitability and financial health of TCBP have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

TCBP Financial Highlights

Over the last trailing twelve months TCBP reported a non-GAAP Earnings per Share(EPS) of -4.21. The EPS decreased by -27216.05% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -71.77%
ROE -293.88%
Debt/Equity 1.07
Chartmill High Growth Momentum
EPS Q2Q%454.43%
Sales Q2Q%-100%
EPS 1Y (TTM)-27216.05%
Revenue 1Y (TTM)-100%

TCBP Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to TCBP. The Buy consensus is the average rating of analysts ratings from 7 analysts.

For the next year, analysts expect an EPS growth of 96.52% and a revenue growth -100% for TCBP


Ownership
Inst OwnersN/A
Ins OwnersN/A
Short Float %0.41%
Short Ratio0.06
Analysts
Analysts82.86
Price Target48.96 (9692%)
EPS Next Y96.52%
Revenue Next Year-100%